Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
JunD proto-oncogene, AP-1 transcription factor subunit (JUND), is an intronless gene encoding a member of the Jun family of basic region-leucine zipper (bZIP) transcription factors[2][3]. JunD forms homodimers or heterodimers (with other Jun or Fos family proteins), participating in the AP-1 transcription factor complex, which regulates the expression of genes involved in cell growth, differentiation, apoptosis, and stress response[1][2][3]. JunD is unique among the Jun family for its ability to generate multiple protein isoforms by alternative translational initiation, which show differential transcriptional activity and protein–protein interaction profiles[1][2]. JunD helps regulate responses to oxidative stress, acts as a negative regulator of Ras-mediated cellular transformation, and protects against senescence and apoptosis. Aberrant JunD function or expression is implicated in various human diseases, including cancer, cardiovascular disease, and metabolic disorders[2][3]. While not an approved drug target, experimental manipulation (e.g., dominant negative ΔJunD) has been explored for scientific and therapeutic research, especially in the context of addiction biology and oncogenesis.
Not applicable for direct pharmacological targeting. For experimental interventions, ΔJunD acts as a dominant negative antagonist of AP-1 transcriptional activity, particularly opposing ΔFosB-mediated transcription.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on JunD proto-oncogene, AP-1 transcription factor subunit (JUND).